NDI-034858, Zasocitinib
$350.00
CAS No.: 2272904-53-5
Catalog No.: 200329
Purity: 95%
MF: C23H24N8O3
MW: 460.498
Storage: 2-8 degree Celsius
SMILES: CO[C@H]1[C@@H](CC1)NC(=O)C=1C=NN2C1N=C(C=C2NC)NC=2C(N(C=CC2)C2=NC=CC=C2)=O
Catalog No.: 200329
Purity: 95%
MF: C23H24N8O3
MW: 460.498
Storage: 2-8 degree Celsius
SMILES: CO[C@H]1[C@@H](CC1)NC(=O)C=1C=NN2C1N=C(C=C2NC)NC=2C(N(C=CC2)C2=NC=CC=C2)=O
CAS No.: 2272904-53-5; NDI-034858, Zasocitinib. PROPERTIES: Zasocitinib (NDI-034858) is a small molecule kinase inhibitor with molecular formula C27H26N6O3. This off-white solid has a molecular weight of approximately 494.54 g/mol. It exhibits limited aqueous solubility but dissolves well in DMSO and other dimethylformamide-based solvents. The compound is hygroscopic and light-sensitive, requiring storage at -80 C under nitrogen atmosphere in amber vials. Safety measures include using a fume hood, wearing respiratory protection, and avoiding skin contact. Zasocitinib is classified as a Category 4 drug hazard. APPLICATIONS: In oncology research, Zasocitinib demonstrates potent inhibition of FLT3 and KIT kinases, making it a valuable tool for studying leukemia pathogenesis, as described in Blood journal. Preclinical studies show its efficacy in FLT3-ITD mutant leukemia models, with findings published in Cancer Cell. In structural biology, Zasocitinib serves as a co-crystallization partner for kinase domain studies, enabling visualization of ATP-binding pocket interactions, as reported in Nature Structural & Molecular Biology. Additionally, it has applications in combination therapies targeting resistant cancer phenotypes, with research detailed in Clinical Cancer Research.
Reviews
Write Your Own Review